<DOC>
	<DOCNO>NCT00518882</DOCNO>
	<brief_summary>This trial conduct Europe United States America ( USA ) . The aim trial compare effect glycaemic control liraglutide exenatide add subject 's ongoing OAD ( oral anti-diabetic drug ) treatment either metformin , sulphonylurea combination subject type 2 diabetes . Two trial period : A 26 week randomise , follow 52 week extension ( 14 + 38 week ) subject receive liraglutide + OAD previous randomisation either liraglutide exenatide , combine OAD treatment .</brief_summary>
	<brief_title>Effect Liraglutide Exenatide Added Ongoing Treatment Blood Glucose Control Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Type 2 diabetes Stable treatment Oral AntiDiabetic Drugs ( metformin , sulphonylurea combination ) least 3 month discretion Investigator HbA1C equal great 7.0 % equal low 11.0 % Body Mass Index ( BMI ) equal low 45.0 kg/m2 Previous treatment insulin Treatment antidiabetic drug metformin sulphonylurea Any previous exposure exenatide liraglutide Impaired liver or/and renal function History significant cardiac event Known retinopathy maculopathy require acute treatment Recurrent major hypoglycaemia hypoglycaemic unawareness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>